Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms~* At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL~* Intact Uterus~Exclusion Criteria:~* Use of oral estrogen, progestin, androgen, or selective estrogen receptor modulator (SERM) containing drug products within 8 weeks before screening~* A history or active presence of clinically important medical disease: eg. cardiovascular disease (stroke, heart attack), chronic renal or liver disease, breast cancer, etc.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): bazedoxifene 20 mg/conjugated estrogens 0.45 mg
- 2 (Type: EXPERIMENTAL): bazedoxifene 20 mg/conjugated estrogens 0.625 mg
- 3 (Type: EXPERIMENTAL): bazedoxifene 20 mg
- 4 (Type: ACTIVE_COMPARATOR): Prempro
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).